Altimmune Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
6.86
0.15
(2.24%)
Volume:
1,696,977
52 week range:
5.28 - 14.84
Market Cap:
487.915M
Company Description:
Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.